<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Russian Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-2106</issn><issn publication-format="electronic">2412-9100</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">643573</article-id><article-id pub-id-type="doi">10.17816/medjrf643573</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Research Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Factors influencing caspase-6 levels in patients with dyspnea associated with long COVID</article-title><trans-title-group xml:lang="ru"><trans-title>Факторы, определяющие изменение активности каспазы-6 у больных с одышкой при длительном постковидном синдроме</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-3364-0591</contrib-id><contrib-id contrib-id-type="spin">4394-5330</contrib-id><name-alternatives><name xml:lang="en"><surname>Masalkina</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Масалкина</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>
</p><p>MD, Cand. Sci. (Medicine), Associate Professor</p>
</bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>omasalkina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0051-6694</contrib-id><contrib-id contrib-id-type="spin">2387-6781</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernyavina</surname><given-names>Anna I.</given-names></name><name xml:lang="ru"><surname>Чернявина</surname><given-names>Анна Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент</p></bio><email>anna_chernyavina@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7003-5186</contrib-id><contrib-id contrib-id-type="spin">1044-0503</contrib-id><name-alternatives><name xml:lang="en"><surname>Koziolova</surname><given-names>Natalya A.</given-names></name><name xml:lang="ru"><surname>Козиолова</surname><given-names>Наталья Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>nakoziolova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3694-3647</contrib-id><contrib-id contrib-id-type="spin">6413-8930</contrib-id><name-alternatives><name xml:lang="en"><surname>Polyanskaya</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Полянская</surname><given-names>Елена Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент</p></bio><email>eapolyanskaya@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician Wagner Perm State Medical University</institution></aff><aff><institution xml:lang="ru">Пермский государственный медицинский университет имени академика Е.А. Вагнера</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-04-27" publication-format="electronic"><day>27</day><month>04</month><year>2025</year></pub-date><volume>31</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>139</fpage><lpage>150</lpage><history><date date-type="received" iso-8601-date="2024-12-31"><day>31</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-03-11"><day>11</day><month>03</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-04-27"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://medjrf.com/0869-2106/article/view/643573">https://medjrf.com/0869-2106/article/view/643573</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND: </bold>Apoptosis is a genetically programmed form of cell death. It is essential for maintaining homeostasis in the body. A key feature of apoptosis is the maintenance of normal cell population, with caspases playing a central role and potentially contributing to the pathogenesis of specific long COVID phenotypes. Identifying the role of caspases and their association with clinical markers may provide additional evidence for the causes of this syndrome.</p> <p><bold>AIM: </bold>To determine the role of caspase-6 in patients with dyspnea or its equivalents in long COVID.</p> <p><bold>METHODS: </bold>A single-center, cross-sectional observational study was conducted over a 3-year period, when 878 patients sought medical care for dyspnea or its equivalents at an outpatient clinic, with 186 patients included in the study.</p> <p><bold>RESULTS: </bold>All patients in the study had caspase-6 levels within the reference range. Caspase-6 concentration in the long COVID group (group 1, <italic>n</italic> = 86) was significantly lower than that in the control group (group 2, <italic>n</italic> = 100) with no history of COVID-19. To identify risk factors for decreased apoptotic activity and increased pro-inflammatory responses, 86 patients with long COVID and dyspnea were stratified into two subgroups based on caspase-6 levels: 33 patients (38.4%) with caspase-6 &gt; 26.5 pg/ml and 53 patients (61.6%) with caspase-6 ≤ 26.5 pg/ml. Severe COVID-19 pneumonia was associated with a nearly 7-fold increase in the relative risk (RR) of reduced apoptotic activity and an increase in pro-inflammatory responses in the post-COVID period: RR 6.85; 95% confidence interval (CI) 1.02–143.74. It also increased the risk of elevated N-terminal pro-B-type natriuretic peptide level &gt; 120 pg/ml by more than 2-fold (RR 2.41; 95% CI 1.27–5.14), carotid-femoral pulse wave velocity &gt; 10.6 m/s by 4-fold (RR 4.10; 95% CI 1.45–11.77), aortic pulse wave velocity &gt; 8.3 m/s by 3-fold (RR 3.22; 95% CI 1.31–9.62), increased ferritin level &gt; 152.5 ng/ml. It reduced transferrin saturation &lt; 19.8% by 2.5-fold (RR 2.49; 95% CI 1.23–5.75), and increased tissue inhibitor of metalloproteinases-1 level &gt; 376.1 ng/ml by 69% (RR 1.69; 95% CI 1.10–2.72).</p> <p><bold>CONCLUSION: </bold>Long COVID-related dyspnea is associated with reduced caspase-6 levels, which correlate with impaired apoptotic activity and heightened inflammatory responses. Proposed pathophysiological mechanisms underlying caspase-6 deficiency include activation of myocardial stress pathways, increased collagen deposition, hyperferritinemia, and arterial stiffness.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Апоптоз представляет собой особую генетически запрограммированную форму гибели клетки и необходимое условие нормального существования организма. Особенностью апоптоза является поддержание нормальной численности клеток, и центральное место в этом процессе занимают каспазы, которые могут играть патогенетическую роль в формировании определённых фенотипов длительного постковидного синдрома. Определение роли каспаз и их взаимосвязи с клиническими маркерами может предоставить дополнительные доказательства причин развития этого синдрома.</p> <p><bold>Цель. </bold>Определить роль каспазы-6 у больных с одышкой или её эквивалентами при длительном постковидном синдроме.</p> <p><bold>Методы. </bold>Проведено наблюдательное одноцентровое одномоментное клиническое исследование, в ходе которого в течение 3 лет в поликлинику по поводу одышки или её эквивалентов обратились 878 пациентов, 186 из которых включено в исследование.</p> <p><bold>Результаты. </bold>У всех больных, включённых в исследование, каспаза-6 была в диапазоне референсных значений. Её активность в группе больных с одышкой при длительном постковидном синдроме (1-я, <italic>n</italic> = 86) была статистически значимо ниже, чем в группе пациентов без данной инфекции в анамнезе (2-я, <italic>n</italic> = 100). С целью определения факторов риска снижения активности апоптоза и развития провоспалительных реакций 86 пациентов с одышкой, перенёсших новую коронавирусную инфекцию, в зависимости от активности каспазы-6 были разделены на 2 подгруппы: 33 пациента (38,4%) с активностью каспазы-6 &gt; 26,5 пг/мл и 53 пациента (61,6%) с активностью каспазы-6 ≤ 26,5 пг/мл. Перенесённая новая коронавирусная инфекция с тяжёлой пневмонией снижает относительный риск (ОР) активности апоптоза и повышает риск провоспалительных реакций в постковидный период почти в 7 раз [ОР 6,85; 95% доверительный интервал (ДИ) 1,02–143,74]; увеличивает концентрацию N-терминального фрагмента мозгового натрийуретического пептида &gt; 120 пг/мл более чем в 2 раза (ОР 2,41; 95% ДИ 1,27–5,14); каротидно-феморальную скорость &gt; 10,6 м/с — в 4 раза (ОР 4,10; 95% ДИ 1,45–11,77); а также скорость пульсовой волны в аорте &gt; 8,3 м/с — в 3 раза (ОР 3,22; 95% ДИ 1,31–9,62); увеличивает концентрацию ферритина &gt; 152,5 нг/мл и снижает коэффициент насыщения трансферрина железом &lt; 19,8% — в 2,5 раза (ОР 2,49; 95% ДИ 1,23–5,75); повышает концентрацию тканевого ингибитора матриксных металлопротеиназ 1-го типа &gt; 376,1 нг/мл — на 69% (ОР 1,69; 95% ДИ 1,10–2,72).</p> <p><bold>Заключение. </bold>Длительный постковидный синдром у пациентов с одышкой взаимосвязан с относительным дефицитом каспазы-6, что ассоциируется со снижением активности апоптоза и увеличением провоспалительных реакций. Предположительными патогенетическими механизмами формирования дефицита каспазы-6 при этом синдроме являются активация миокардиального стресса, повышенное коллагенообразование, гиперферритинемия и увеличение артериальной жёсткости.</p></trans-abstract><kwd-group xml:lang="en"><kwd>long COVID</kwd><kwd>caspase-6</kwd><kwd>dyspnea</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>длительный постковидный синдром</kwd><kwd>каспаза-6</kwd><kwd>одышка</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015;16(9):907–917. doi: 10.1038/ni.3253 EDN: XYOSRD</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol. 2018;36:489–517. doi: 10.1146/annurev-immunol-042617-053010 EDN: VFAEPR</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev. 2020;297(1):26–38. doi: 10.1111/imr.12909 EDN: UJDAZU</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zheng M, Karki R, Vogel P, Kanneganti TD. Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell. 2020;181(3):674–687.e13. doi: 10.1016/j.cell.2020.03.040 EDN: WRJRSM</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Svandova E, Vesela B, Janeckova E, et al. Exploring caspase functions in mouse models. Apoptosis. 2024;29(7-8):938–966. doi: 10.1007/s10495-024-01976-z EDN: OAAUMY</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Man SM, Kanneganti TD. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 2016;16(1):7–21. doi: 10.1038/nri.2015.7 EDN: WSKJHD</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Qi L, Wang L, Jin M, et al. Caspase-6 is a key regulator of cross-talk signal way in PANoptosis in cancer. Immunology. 2023;169(3):245–259. doi: 10.1111/imm.13633 EDN: JEYFBI</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Shoshan-Barmatz V, Arif T, Shteinfer-Kuzmine A. Apoptotic proteins with non-apoptotic activity: expression and function in cancer. Apoptosis. 2023;28(5-6):730–753. doi: 10.1007/s10495-023-01835-3 EDN: LBHRFM</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Tisch N, Freire-Valls A, Yerbes R, et al. Caspase-8 modulates physiological and pathological angiogenesis during retina development. J Clin Invest. 2019;129(12):5092–5107. doi: 10.1172/JCI122767</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zheng M, Williams EP, Malireddi RKS, et al. Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. J Biol Chem. 2020;295(41):14040–14052. doi: 10.1074/jbc.RA120.015036 EDN: VUURED</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023? Pol Arch Intern Med. 2023;133(4):16402. doi: 10.20452/pamw.16402 EDN: NPXPJZ</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Premeaux TA, Yeung ST, Bukhari Z, et al. Emerging insights on caspases in COVID-19 pathogenesis, sequelae, and directed therapies. Front Immunol. 2022;13:842740. doi: 10.3389/fimmu.2022.842740 EDN: IUQIGY</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cezar R, Kundura L, André S, et al. T4 apoptosis in the acute phase of SARS-CoV-2 infection predicts long COVID. Front Immunol. 2024;14:1335352. doi: 10.3389/fimmu.2023.1335352 EDN: BZWLIB</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Uribe V, Wong BK, Graham RK, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet. 2012;21(9):1954–1967. doi: 10.1093/hmg/dds005</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457(7232):981–989. doi: 10.1038/nature07767 Retracted in: Nature. 2024;625(7993):204. doi: 10.1038/s41586-023-06943-3</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Colarusso C, Terlizzi M, Maglio A, et al. Activation of the AIM2 receptor in circulating cells of post-COVID-19 patients with signs of lung fibrosis is associated with the release of IL-1α, IFN-α and TGF-β. Front Immunol. 2022;13:934264. doi: 10.3389/fimmu.2022.934264 EDN: VFUIRU</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang D, Yu S, Zhang Y, et al. Caspse-11-GSDMD pathway is required for serum ferritin secretion in sepsis. Clin Immunol. 2019;205:148–152. doi: 10.1016/j.clim.2018.11.005</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Volfovitch Y, Tsur AM, Gurevitch M, et al. The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis. Immunol Res. 2022;70(6):817–828. doi: 10.1007/s12026-022-09312-w EDN: GSVZCQ</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Watanabe C, Shu GL, Zheng TS, et al. Caspase 6 regulates B cell activation and differentiation into plasma cells. J Immunol. 2008;181(10):6810–6819. doi: 10.4049/jimmunol.181.10.6810</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Suresh K, Carino K, Johnston L, et al. A nonapoptotic endothelial barrier-protective role for caspase-3. Am J Physiol Lung Cell Mol Physiol. 2019;316(6):L1118–L1126. doi: 10.1152/ajplung.00487.2018</mixed-citation></ref></ref-list></back></article>
